Executive Committee: Biora Therapeutics, Inc.

Manager
Positions heldSince
Adi Mohanty

Adi Mohanty

59 year

Chief Executive Officer 2021-11-07
Eric d'Esparbes

Eric d'Esparbes

58 year

Director of Finance/CFO 2019-04-30
Clarke Neumann

Clarke Neumann

62 year

General Counsel 2014-08-31
Corporate Secretary 2014-08-31
Robyn Hatton

Robyn Hatton

Human Resources Officer 2019-09-30
Paul W. Shabram

Paul W. Shabram

Chief Tech/Sci/R&D Officer 2022-04-24
Sharat Singh

Sharat Singh

Chief Tech/Sci/R&D Officer -
Ariella Kelman

Ariella Kelman

Chief Tech/Sci/R&D Officer 2023-04-30

Composition of the Board of Directors: Biora Therapeutics, Inc.

Director
CommitteesSince
Jeffrey Alter

Jeffrey Alter

63 year

Audit Committee 2021-10-31
Governance Committee 2021-10-31
Nominating Committee 2021-10-31
Jill Howe

Jill Howe

50 year

Governance Committee 2021-11-02
Nominating Committee 2021-11-02
Audit Committee Chair 2021-11-02
Jeffrey Allen Ferrell

Jeffrey Allen Ferrell

51 year

Compensation Committee 2014-05-31
Governance Committee Chair 2014-05-31
Nominating Committee Chair 2014-05-31
Brian Kotzin

Brian Kotzin

76 year

Compensation Committee Chair 2019-05-31
Lynne Powell

Lynne Powell

59 year

Audit Committee 2019-01-31
Adi Mohanty

Adi Mohanty

59 year

Director/Board Member 2021-11-07

Former Officers and Directors: Biora Therapeutics, Inc.

Insider
Positions held
SinceUntil
Surbhi Sarna
Surbhi Sarna
Director/Board Member 2021-06-30 2023-06-13
Independent Dir/Board Member 2021-06-30 2023-06-13
Hutan Hashemi
Hutan Hashemi
Compliance Officer 2019-04-30 2022-02-28
Damon Silvestry
Damon Silvestry
Chief Operating Officer 2020-05-25 2022-02-11
Sean Lavin
Sean Lavin
Investor Relations Contact 2021-05-24 2021-10-31
Regan Lauer
Regan Lauer
Comptroller/Controller/Auditor 2019-09-30 2021-10-31
Samuel R. Nussbaum
Samuel R. Nussbaum
Director/Board Member 2018-12-31 2021-09-22
Independent Dir/Board Member 2018-12-31 2021-09-22
Harry Stylli
Harry Stylli
Chief Executive Officer 2018-07-31 2021-08-31
Chairman 2018-07-31 2021-08-31
Founder 2009-12-31 2021-08-31
Sami Shihabi
Sami Shihabi
Corporate Officer/Principal 2019-09-30 2021-08-05
Emil Chuang
Emil Chuang
Corporate Officer/Principal 2018-06-30 2020-11-30
Mitchell Jones
Mitchell Jones
Corporate Officer/Principal 2015-04-30 2020-06-30
Nichole L. Martin
Nichole L. Martin
Corporate Officer/Principal 2018-05-31 2020-04-30
Troy Seelye
Troy Seelye
Chief Tech/Sci/R&D Officer 2020-02-29 -
Timothy E. Cloutier
Timothy E. Cloutier
Corporate Officer/Principal 2016-04-30 2019-03-31
John Bigalke
John Bigalke
Director/Board Member 2018-12-31 -
Independent Dir/Board Member 2018-12-31 -
Allison Luo
Allison Luo
Corporate Officer/Principal 2017-05-31 2018-07-31
Sumit Aggarwal
Sumit Aggarwal
Director of Finance/CFO 2014-12-31 2017-12-31
President 2014-12-31 2017-12-31
Matthew Cooper
Matthew Cooper
Chief Tech/Sci/R&D Officer 2015-02-28 -
Corporate Officer/Principal 2015-02-28 -
George Gianakopoulos
George Gianakopoulos
Sales & Marketing 2019-09-30 -
Paul W. Hawran
Paul W. Hawran
Founder 2009-12-31 -
Lawrence Mertz
Lawrence Mertz
Chief Tech/Sci/R&D Officer - -
Chris Wahl
Chris Wahl
Corporate Officer/Principal - -
Howard Slutsky
Howard Slutsky
Director/Board Member - -

Age distribution of managers

Parity Men Women

Male11
Female3

Of which Executive Committee

Male6
Female1

Of which Directors

Male4
Female2
Logo Biora Therapeutics, Inc.
Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Company’s pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. It has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.
Employees
58

Departures of Key Persons

Harry Stylli
-
Harry Stylli

Chief Executive Officer

2018-07-31 2021-08-31